腎がん薬物療法の進歩～根治を目指して～

腎がん薬物療法の進歩～根治を目指して～

by 三宅秀明 (Miyake Hideaki)

Life & Natural Systems Medicine & Health MJCLOncologyMJCL2Chemotherapy
🎙 三宅秀明 (Miyake Hideaki) 👥 5K 📅 May 15, 2026 ⏱ 22 min 👁 439 📄 expert opinion 🧭 2026-08-16
Available in: English (current) Français

Keywords

renal cell carcinomadrug therapyimmunotherapymolecular targeted therapyprognosis

Summary

This lecture by Professor Hideaki Miyake from Kobe University provides an overview of the evolution and current state of drug therapy for renal cell carcinoma (RCC). The presentation begins with the characteristics of RCC, highlighting its high vascularity and immunogenicity, which make it resistant to conventional chemotherapy and radiation. The speaker traces the history of treatment from the cytokine era (pre-2006) to the introduction of molecular targeted agents (2006) and immune checkpoint inhibitors (2016), noting significant improvements in overall survival from about 1 year to over 5 years. He discusses the risk classification (favorable, intermediate, poor) and the standard first-line treatments, which are now based on immune checkpoint inhibitor combinations. He presents data from clinical trials, such as the combination of pembrolizumab and lenvatinib, showing high response rates and durable responses. He also mentions the use of drug therapy in the neoadjuvant and adjuvant settings to facilitate surgery and prevent recurrence. The lecture concludes with a Q&A session where he addresses questions about tumor shrinkage and surgery, risk classification for non-clear cell RCC, and the role of cytokines in the past.

181 words

Critical Evaluation

Value of the Information & Strength of the Argument

The lecture provides valuable, up-to-date information on the treatment of renal cell carcinoma, clearly explaining the mechanisms of action of molecular targeted agents and immune checkpoint inhibitors. The argumentation is solid, supported by clinical trial data and real-world evidence from the speaker’s own institution. The speaker effectively communicates complex concepts in an accessible manner, using analogies to illustrate the characteristics of different drug classes. The presentation is well-structured, progressing from historical context to current standards and future directions.

87 words

Title / Content Match

The title accurately reflects the content, which focuses on advances in drug therapy for renal cell carcinoma aiming for cure.

Quality & Reliability

8/10

The lecture is given by a professor of urology at Kobe University, presenting established clinical data and real-world evidence. The content aligns with current medical knowledge and guidelines, but lacks detailed citations to specific studies or references.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

Concurring Sources

Contribution & Novelties

The lecture provides a comprehensive and up-to-date overview of drug therapy for renal cell carcinoma, emphasizing the shift towards immune checkpoint inhibitor combinations and the potential for cure. It also highlights the use of drug therapy in perioperative settings, which is a relatively recent development. The speaker’s real-world data from Kobe University adds practical insight.

Pour aller plus loin :

101 words

Radar Profile

The radar profile shows high scores in quantity and quality of information, reflecting the comprehensive and evidence-based content. The technical level is moderate, suitable for a medical audience, and the reliability is high due to the speaker's expertise and use of clinical data.

Reliability 8/10

💬 No comments were provided for analysis.